CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer: Trials & Insights
Summary of Key Points from the onclive Interview with Dr. Desai on CDK4/6 Inhibitors in Breast Cancer:
Here’s a breakdown of the key takeaways from the interview:
1. Clinical Trials & Efficacy:
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) consistently improve Progression-Free Survival (PFS) in metastatic HR-positive, HER2-negative breast cancer.
Ribociclib has demonstrated a statistically notable advancement in Overall survival (OS).
Abemaciclib showed a clinically meaningful, though not statistically significant, OS benefit (13.1-month improvement).
Palbociclib trials haven’t shown statistically significant OS improvement, but some real-world data and criticisms of data collection suggest potential benefits.
All three drugs are approved for use in the metastatic setting.
2. Selecting a CDK4/6 Inhibitor:
Dr. Desai keeps all three drugs as options,typically using them in the first or second line of treatment.
Selection is based on:
Patient age and comorbidities
Treatment tolerability
Potential adverse effects (AEs)
Preference: Dr. Desai leans towards ribociclib and abemaciclib due to their OS benefits.
Palbociclib is frequently enough preferred for older patients with comorbidities who might potentially be less able to tolerate the side effects of abemaciclib (diarrhea, fatigue) or have cardiac concerns that might interact with ribociclib.
3. Palbociclib in HER2-Positive Breast Cancer:
The PATINA trial showed that adding palbociclib to standard treatment (trastuzumab, pertuzumab, and endocrine therapy) for HR-positive, HER2-positive metastatic breast cancer resulted in a 15.2-month improvement in PFS.
Overall survival (OS) data from the PATINA trial are not yet mature.
* This represents a potential new approach to maintenance therapy in this patient population, following induction with taxane, trastuzumab, and pertuzumab.
In essence, the interview highlights the established role of CDK4/6 inhibitors in HR+/HER2- breast cancer and the emerging potential of palbociclib in HER2+ disease, emphasizing the importance of individualized treatment decisions based on patient characteristics and potential side effects.